NSE: STAR | BSE: 532531

Strong Performer

Download real time

863.70 18.70 (2.21%)

48.44% Fall from 52W High

277.6K NSE+BSE Volume

NSE 29 Aug, 2025 3:31 PM (IST)

7,961

Market Cap

Above industry Median

1.1

Beta 1Year

High Volatility

Strides Pharma Science Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for STAR, BSE:532531 Strides Pharma Science Ltd.

Strides Pharma Science Ltd.

16 Nov 2022

863.70

2.21%

Strong recovery in US sales

Buy: Strides Pharma Science Ltd.

ICICI Securities Limited

Strides Pharma Science’s (Strides) Q2FY23 performance fell short of our estimates due to underperformance in regulated markets other than the US, which reported strong recovery with a 30% QoQ rise to US$60mn.

Strides Pharma Scien.. has an average target of 1874.00 from 1 broker.

Strides Pharma Science Ltd.

11 Aug 2022

863.70

2.21%

STRIDES PHARMA SCIENCE LIMITED

Accumulate: Strides Pharma Science Ltd.

Target

Geojit BNP Paribas

Strides Pharma Science Ltd. is trading above its 200 day SMA of 799.9

Strides Pharma Science Ltd.

23 Jun 2022

863.70

2.21%

STRIDES PHARMA SCIENCE LIMITED

Accumulate: Strides Pharma Science Ltd.

Target

Geojit BNP Paribas

Strides Pharma Science Ltd. has gained 20.78% in the last 3 Months

Strides Pharma Science Ltd.

25 May 2022

863.70

2.21%

Performance on a gradual recovery mode

Buy: Strides Pharma Science Ltd.

Target

Motilal Oswal

Strides Pharma Science Ltd. is trading below its 30 day SMA of 871.1

Strides Pharma Science Ltd.

24 Nov 2021

863.70

2.21%

STRIDES PHARMA SCIENCE LIMITED

Accumulate: Strides Pharma Science Ltd.

Recommendation Target

Geojit BNP Paribas

Strides reported its Q2FY22 revenue at Rs. 721cr, (4.8% QoQ, -9% YoY), enabled by a bounce back in the other regulated markets which was partially offset by an underperformance in the US markets. US markets (34% of total revenues) witnessed a 17% QoQ/-38% YoY...

Strides Pharma Science Ltd. is trading above its 200 day SMA of 799.9

Strides Pharma Science Ltd.

11 Nov 2021

863.70

2.21%

US segment drags overall performance

Buy: Strides Pharma Science Ltd.

Target

Motilal Oswal

STR reported a lower than expected performance in 2QFY22 due to continued headwinds in the US business. Sales in other regulated markets witnessed a recovery, with an 18% YoY growth. With the completion of Endo products and facility acquisition, STR will have a diversified US portfolio, with a lower proportion of Acute products as well as differentiated products such as hormones, Nasal Sprays, Gels, Modified Release products, and controlled substances, which are less susceptible to price shocks like that seen in 1HFY22. Other regulated/emerging markets are...

Number of FII/FPI investors increased from 268 to 287 in Jun 2025 qtr.

Strides Pharma Science Ltd.

13 Aug 2021

863.70

2.21%

STRIDES PHARMA SCIENCE LIMITED

Buy: Strides Pharma Science Ltd.

Target

Geojit BNP Paribas

Strides reported a weak quarter witnessing a de-growth across revenues of 12% YoY to Rs.688cr during Q1FY22 owing to major sector headwinds such as high logistics cost, price erosion and increased competition. US markets saw a decline of -25% due to double digit price erosion, lower prescription rates and elective surgeries. Other regulated markets were at $30m from $35m in Q1FY21 due to lockdowns in the UK leading to supply chain disruptions. Institutional business was subdued by 33% on account of lower take off of TLD in the quarter. However, the African business reported a 4% QoQ growth despite lower demand for acute...

Promoters unpledged 1.88% of shares in last quarter. Total pledge stands at 50.10% of promoter holdings

Strides Pharma Science Ltd.

07 Aug 2021

863.70

2.21%

Lack of launches / COVID disruption leads to weak 1QFY22

Buy: Strides Pharma Science Ltd.

Target

Motilal Oswal

Strides Pharma (STR) reported unexpected operational loss in 1QFY22 on lower demand, higher competitive intensity in US Generics, and low operating leverage. This was exacerbated by the impact on production and supply due to a severe second COVID wave in Bengaluru. As a quick mitigation plan to increase product launches, it aims to acquire a portfolio of differentiated ANDAs, including 20 already commercialized products and a manufacturing facility from Endo Pharma in the US. The acquisition would double the approved product portfolio and add...

Strides Pharma Science Ltd. has lost -33.85% in the last 1 Year

Strides Pharma Science Ltd.

03 Jun 2021

863.70

2.21%

STRIDES PHARMA SCIENCE LIMITED

Buy: Strides Pharma Science Ltd.

Recommendation Target

Geojit BNP Paribas

The emerging markets grew by 107% YoY with growth in institutional biz. driven by TDL. The company announced its partnership with TLC to launch Amphotericin B Liposome for Injection 50mg. We expect a revenue CAGR of 15% over FY21E-FY23E on the back of strong existing product portfolio, new product basket to aid COVID treatment and strengthening of front-end presence. Hence, we upgrade our rating from Accumulate to Buy based on...

Promoters unpledged 1.88% of shares in last quarter. Total pledge stands at 50.10% of promoter holdings

Strides Pharma Science Ltd.

28 May 2021, 12:00AM

863.70

2.21%

US/Institutional business drives earnings

Buy: Strides Pharma Science Ltd.

Target

Motilal Oswal

STR's 4QFY21 operational performance was marginally below our estimate. The robust performance in the US/Institutional segment within emerging markets was offset by subdued sales in other regulated markets on account of COVID-19. In addition to commercial manufacturing of the Sputnik vaccine by Oct'21, STR is building a basket of COVID-related medicines. The...

Strides Pharma Science Ltd. has gained 36.48% in the last 6 Months

Is Strides Pharma Science Ltd. worth buying?

489 Votes:

Buy 78.73%

Sell 11.86%

Hold 9.41%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Sell SEE REPORTS >

pdf